Novartis Secures Approval for First Malaria Drug for Infants and Newborns

In a significant medical breakthrough, Novartis has received regulatory approval for the first-ever malaria treatment specifically developed for newborns and infants. The new formulation, tailored for vulnerable age groups, addresses a critical gap in paediatric malaria care.

Named Coartem 20/120mg Dispersible, the drug is designed for babies weighing 5kg and above typically as young as two months old. Until now, no WHO-prequalified treatment existed for this demographic, leaving millions at risk in malaria-endemic regions.

This paediatric formulation dissolves easily in water, ensuring faster absorption and easier administration. With malaria continuing to claim hundreds of thousands of lives annually many of them children under five this development marks a vital step forward.

Novartis aims to make the treatment widely accessible through global partnerships, reinforcing its commitment to combatting one of the world’s deadliest infectious diseases.
*This news has been published on Times of India on 9th July 2025.

 

 

 

Source Click